MBX (MBX Biosciences) EBITDA Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. MBX Biosciences's EBITDA for the three months ended in Dec. 2024 was $-18.55 Mil. MBX Biosciences's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, MBX Biosciences's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

MBX Biosciences EBITDA Margin % Historical Data

The historical data trend for MBX Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences EBITDA Margin % Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

EBITDA Margin %

MBX Biosciences Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of MBX Biosciences's EBITDA Margin %

For the Biotechnology subindustry, MBX Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

MBX Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

MBX Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-67.95	/	0
	=	%

MBX Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-18.552	/	0
	=	%

MBX Biosciences (NAS:MBX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

MBX Biosciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.